Business
Posting of Annual Report and Notice of AGM
Posting of Annual Report and Notice of AGM.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n \nRNS Number : 2002A Hemogenyx Pharmaceuticals PLC 28 May 2019 \n\nHemogenyx Pharmaceuticals plc\n(\"Hemogenyx\" or the \"Company\")\n \nPosting of Annual Report & Notice of Annual General Meeting\n \nHemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, confirms that the Annual Report and Accounts for the year ended 31 December 2018 (\"2018 Annual Report\"), the Notice of the Annual General Meeting and a Form of Proxy are now available on the Company's website:\nhttps://hemogenyx.com/investors/annual-and-half-year-reports/default.aspx\n \nThe 2018 Annual Report will be posted to shareholders today.\n \nThe AGM is to be held on 28 June 2019 at 11am at the offices of Osborne Clarke LLP, One London Wall, London EC2Y 5EB.\n \n \nEnquiries:\n\n\n\nHemogenyx Pharmaceuticals plc\n\n\nwww.hemogenyx.com\n\n\n\n\nDr Vladislav Sandler, Chief Executive Officer & Co-Founder\n\n\[email protected]\n\n\n\n\nSir Marc Feldmann, Executive Chairman\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSP Angel Corporate Finance LLP\n\n\nTel: +44 (0)20 3470 0470\n\n\n\n\nMatthew Johnson, Vadim Alexandre, Soltan Tagiev\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPeterhouse Corporate Finance Limited\n\n\nTel: +44 (0)20 7469 0930\n\n\n\n\nLucy Williams, Duncan Vasey\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nUS Media enquiries\n\n\nTel: +1 (323) 646-3249\n\n\n\n\nLowell Goodman\n\n\[email protected] \n\n\n\n \n \nAbout Hemogenyx Pharmaceuticals plc\nHemogenyx Pharmaceuticals plc (\"Hemogenyx\") is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly-owned US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility and a wholly-owned Belgian operating subsidiary, Hemogenyx-Cell SPRL, located in Liège.\nHemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product deve...